New Advances in Nasopharyngeal and Oropharyngeal Cancer Treatment

Dear Colleagues,

Oropharyngeal and nasopharyngeal carcinomas represent a significant therapeutic challenge for head and neck surgeons and oncologists. Unlike most head and neck tumors, which are typically solely linked to traditional risk factors such as smoking and alcohol consumption, these two tumor types may also be associated with the oncogenic activity of viruses, namely EBV and HPV. This can have significant prognostic and therapeutic implications. Another factor that complicates the treatment of these tumors is their location and the difficulty in identifying the primary tumor, especially when they arise as small microtumors in the Waldeyer’s ring, where it can be very challenging to distinguish between flogistic and neoplastic activity. Consequently, these tumors may often be misclassified as neck metastases from an occult tumor, as the primary tumor cannot always be identified. With a better understanding of the biomolecular mechanisms underlying these tumors and thanks to the medical and surgical innovations driven by scientific and technological progress, patients with these tumors can now benefit from high-quality treatments, even in the relapsed and metastatic setting. This Special Issue aims to highlight the therapeutic advances made in the treatment of these insidious head and neck tumors to ensure the best possible care for patients.

Dr. Giovanni Motta
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• oropharyngeal squamous cell carcinoma (OPSCC)
• nasopharyngeal carcinoma (NPC)
• EBV
• P16
• HPV
• head and neck oncology
• neck cancer from unknown primary (NCUP)
• de-intensification
• immunotherapy
• transoral robotic surgery (TORS)
• neck dissection